Podocytopathy in diabetes

A metabolic and endocrine disorder

Ana Diez-Sampedro, Oliver Lenz, Alessia Fornoni

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Diabetic nephropathy (DN) represents a major public health cost. Tight glycemic and blood pressure control can dramatically slow, but not stop, the progression of the disease, and a large number of patients progress toward end-stage renal disease despite currently available interventions. An early and key event in the development of DN is loss of podocyte function (or glomerular visceral epithelial cells) from the kidney glomerulus, where they contribute to the integrity of the glomerular filtration barrier. Recent evidence suggests that podocytes can be the direct target of circulating hormones, lipids, and adipokines that are affected in diabetes. We review the clinical and experimental evidence implicating novel endocrine and metabolic pathways in the pathogenesis of podocyte dysfunction and the development of DN.

Original languageEnglish
Pages (from-to)637-646
Number of pages10
JournalAmerican Journal of Kidney Diseases
Volume58
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Podocytes
Diabetic Nephropathies
Glomerular Filtration Barrier
Kidney Glomerulus
Adipokines
Metabolic Networks and Pathways
Health Care Costs
Chronic Kidney Failure
Disease Progression
Public Health
Hormones
Blood Pressure
Lipids

Keywords

  • Diabetic nephropathy
  • hormones
  • podocytes
  • proteinuria

ASJC Scopus subject areas

  • Nephrology

Cite this

Podocytopathy in diabetes : A metabolic and endocrine disorder. / Diez-Sampedro, Ana; Lenz, Oliver; Fornoni, Alessia.

In: American Journal of Kidney Diseases, Vol. 58, No. 4, 01.10.2011, p. 637-646.

Research output: Contribution to journalArticle

@article{1318337dd3604ba88b56733712d6c53b,
title = "Podocytopathy in diabetes: A metabolic and endocrine disorder",
abstract = "Diabetic nephropathy (DN) represents a major public health cost. Tight glycemic and blood pressure control can dramatically slow, but not stop, the progression of the disease, and a large number of patients progress toward end-stage renal disease despite currently available interventions. An early and key event in the development of DN is loss of podocyte function (or glomerular visceral epithelial cells) from the kidney glomerulus, where they contribute to the integrity of the glomerular filtration barrier. Recent evidence suggests that podocytes can be the direct target of circulating hormones, lipids, and adipokines that are affected in diabetes. We review the clinical and experimental evidence implicating novel endocrine and metabolic pathways in the pathogenesis of podocyte dysfunction and the development of DN.",
keywords = "Diabetic nephropathy, hormones, podocytes, proteinuria",
author = "Ana Diez-Sampedro and Oliver Lenz and Alessia Fornoni",
year = "2011",
month = "10",
day = "1",
doi = "10.1053/j.ajkd.2011.03.035",
language = "English",
volume = "58",
pages = "637--646",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Podocytopathy in diabetes

T2 - A metabolic and endocrine disorder

AU - Diez-Sampedro, Ana

AU - Lenz, Oliver

AU - Fornoni, Alessia

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Diabetic nephropathy (DN) represents a major public health cost. Tight glycemic and blood pressure control can dramatically slow, but not stop, the progression of the disease, and a large number of patients progress toward end-stage renal disease despite currently available interventions. An early and key event in the development of DN is loss of podocyte function (or glomerular visceral epithelial cells) from the kidney glomerulus, where they contribute to the integrity of the glomerular filtration barrier. Recent evidence suggests that podocytes can be the direct target of circulating hormones, lipids, and adipokines that are affected in diabetes. We review the clinical and experimental evidence implicating novel endocrine and metabolic pathways in the pathogenesis of podocyte dysfunction and the development of DN.

AB - Diabetic nephropathy (DN) represents a major public health cost. Tight glycemic and blood pressure control can dramatically slow, but not stop, the progression of the disease, and a large number of patients progress toward end-stage renal disease despite currently available interventions. An early and key event in the development of DN is loss of podocyte function (or glomerular visceral epithelial cells) from the kidney glomerulus, where they contribute to the integrity of the glomerular filtration barrier. Recent evidence suggests that podocytes can be the direct target of circulating hormones, lipids, and adipokines that are affected in diabetes. We review the clinical and experimental evidence implicating novel endocrine and metabolic pathways in the pathogenesis of podocyte dysfunction and the development of DN.

KW - Diabetic nephropathy

KW - hormones

KW - podocytes

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=80053052721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053052721&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2011.03.035

DO - 10.1053/j.ajkd.2011.03.035

M3 - Article

VL - 58

SP - 637

EP - 646

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -